Projecting the benefits of antiretroviral therapy for HIV prevention: The impact of population mobility and linkage to care

Journal of Infectious Diseases

Volumn 206, Issue 4, 2012, Pages 543-551

  Andrews, Jason R ^a   Wood, Robin ^c   Bekker, Linda Gail ^c   Middelkoop, Keren ^c   Walensky, Rochelle P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Harvard Initiative for Global Health   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DEMOGRAPHY; HEALTH CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRATION; MORBIDITY; POPULATION MIGRATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS TRANSMISSION; ADOLESCENT; DISEASE TRANSMISSION; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; MIGRATION; PATIENT ATTITUDE; SOUTH AFRICA; THEORETICAL MODEL;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, INFECTIOUS; EMIGRATION AND IMMIGRATION; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; PATIENT ACCEPTANCE OF HEALTH CARE; SOUTH AFRICA;

EID: 84866924370     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis401     Document Type: Article

References (34)

1. Montaner JSG, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-6.
2. El-Sadr WM, Affrunti M, Gamble T, Zerbe A. Antiretroviral therapy: a promising HIV prevention strategy? J Acquir Immune Defic Syndr 2010; 55(Suppl 2):S116-21.
3. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-4.
4. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-52.
5. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
6. Cohen MS, Mastro TD, Cates W Jr. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1077; author reply 1080-1.
7. Epstein H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1078-9; author reply 1080-1.
8. Hsieh Y-H, de Arazoza H. Universal voluntary HIV testing and immediate antiretroviral therapy. The Lancet 2009; 373:1079-80.
9. Ruark A, Shelton JD, Halperin DT, Wawer MJ, Gray RH. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1078; author reply 1080-1.
10. Wilson DP. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1077-8.
11. Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis 2010; 50(Suppl 3):S149-55.
12. Kranzer K, Zeinecker J, Ginsberg P, et al. Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One 2010; 5:e13801.
13. Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa? not everyone who should. AIDS 2010; 24 (Suppl 1):S37-44.
14. Losina E, Bassett IV, Giddy J, et al. The "ART" of linkage: pretreatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One 2010; 5:e9538.
15. Polzer T. Population movements in and to South Africa. 2010. http://www.migration.org.za/report/polzer-t-2010-population-movements-andsouth- africa-acms-fact-sheet-june-2010. Accessed 17 January 2012.
16. Govindasamy D, van Schaik N, Kranzer K, Wood R, Mathews C, Bekker L-G. Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Acquir Immune Defic Syndr 2011; 58:344-52. http://www.ncbi.nlm. nih.gov/pubmed/21836524. Accessed 29 August 2011.
17. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by "Test and Treat" in hyper-endemic settings. AIDS 2010; 24:729-35.
18. Stein M. Large sample properties of simulations using Latin hypercube sampling. Technometrics 1987; 29:143-51.
19. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 62:229-43.
20. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998; 4:673-8.
21. United Nations Population Fund. State of the world population 2007: unleashing the potential of urban growth. New York: United Nations Population Fund, 2007.
22. Camlin CS, Hosegood V, Newell M-L, McGrath N, Bärnighausen T, Snow RC. Gender, migration and HIV in rural KwaZulu-Natal, South Africa. PLoS One 5 2010; 57:e11539.
23. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15(Suppl 1):1-15.
24. HIV Prevention Trials Network. Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN Study 052). 2011. http://www.hptn.org/web%20documents/PressReleases/ HPTN052PressReleaseFINAL5-12- 118am.pdf. Accessed 5 July 2011.
25. Granich R, Gupta S, Suthar AB, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011; 9(6):446-69. http://www.ncbi.nlm.nih.gov/pubmed/219 99779. Accessed 12 December 2011.
26. Kranzer K, van Schaik N, Karmue U, et al. High prevalence of selfreported previously undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in a South African community. PLoS One 2011; 69:e25244.
27. Kranzer K, Lewis JJ, Ford N, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 2010; 55:e17-23.
28. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-7.
29. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
30. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-9.
31. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-93.
32. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-404.
33. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-8.
34. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.